Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR

International Journal of Hematology

Volumn 89, Issue 4, 2009, Pages 482-488

  Yamamoto, Masahide ^a   Kakihana, Kazuhiko ^a   Ohashi, Kazuteru ^a   Yamaguchi, Toshikazu ^b   Tadokoro, Kenichi ^b   Akiyama, Hideki ^a   Sakamaki, Hisashi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b BML   (Japan)

Author keywords

Chronic myeloid leukemia; Imatinib; Invader assay; T315I mutation

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; IMATINIB;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTHRALGIA; ARTICLE; BIOASSAY; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT OUTCOME; GENETIC PROCEDURES; GENETICS; MIDDLE AGED; MUTATION;

ADULT; AGED; FEMALE; FUSION PROTEINS, BCR-ABL; GENETIC TECHNIQUES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION;

EID: 67449116509     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0290-9     Document Type: Article

References (23)

1. A Hochhaus P La Rosée 2004 Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance Leukemia 18 1321 1331 10.1038/sj.leu.2403426 (Pubitemid 39136739)
2. A Hochhaus S Kreil AS Corbin 2002 Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2190 2196 10.1038/sj.leu.2402741 (Pubitemid 35331833)
3. AS Corbin P La Rosée EP Stoffregen 2003 Several BCR-ABL kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib Blood 101 4611 4614 10.1182/blood-2002-12-3659 (Pubitemid 36857835)
4. MR Burgess BJ Skaggs NP Shah 2005 Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance Proc Natl Acad Sci USA 102 3395 3400 10.1073/pnas. 0409770102 (Pubitemid 40328056)
5. NP Shah C Tran FY Lee 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 399 401 10.1126/science.1099480 (Pubitemid 38938156)
6. T O'Hare AS Corbin BJ Druker 2006 Targeted CML therapy: controlling drug resistance, seeking cure Curr Opin Genet Dev 16 92 99 10.1016/j.gde.2005.11.002 (Pubitemid 43089618)
7. MA Young NP Shah LH Chao 2006 Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680 Cancer Res 66 1007 1014 10.1158/0008-5472.CAN-05-2788 (Pubitemid 43168337)
8. FJ Giles J Cortes D Jones 2007 MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation Blood 109 500 502 10.1182/blood-2006-05-025049 (Pubitemid 46105945)
9. SG Willis T Lange S Demehri 2005 High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood 106 2128 2137 10.1182/blood-2005-03-1036 (Pubitemid 41291730)
10. J Cortes E Jabbour H Kantarjian 2007 Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 110 4005 4011 10.1182/blood-2007-03-080838 (Pubitemid 350248456)
11. E Jabbour H Kantarjian D Jones 2008 Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Blood 112 53 55 10.1182/blood-2007-11-123950
12. T Ernst P Erben MC Müller 2008 Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib Haematologica 93 186 192 10.3324/haematol.11993
13. N Kono K Ohashi Y Okuyama 2001 Treatment of relapsing Ph+ acute lymphoblastic leukemia with donor leukocyte infusion followed by quantitative monitoring of residual disease Hematology 6 261 265
14. Y Mashima M Nagano T Funayama 2004 Rapid quantification of the heteroplasmy of mutant mitochondrial DNAs in Leber's hereditary optic neuropathy using the Invader technology Clin Biochem 37 268 276 10.1016/j.clinbiochem. 2003.11.011 (Pubitemid 38314880)
15. JG Hall PS Eis SM Law 2000 Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction Proc Natl Acad Sci USA 97 8272 8277 10.1073/pnas.140225597 (Pubitemid 30639662)
16. RW Kwiatkowski V Lyamichev M de Arruda B Neri 1999 Clinical, genetic, and pharmacogenetic applications of invader assay Mol Diagn 4 353 364 10.1016/S1084-8592(99)80012-5
17. T Hughes M Deininger A Hochhaus 2006 Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 28 37 10.1182/blood-2006- 01-0092 (Pubitemid 43990609)
18. S Hayette M Michallet ML Baille 2005 Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients Leuk Res 29 1073 1077 10.1016/j.leukres.2005. 02.006 (Pubitemid 40982602)
19. C Roche-Lestienne JL Lai S Darre 2003 A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia N Engl J Med 348 2265 2266 10.1056/NEJMc035089 (Pubitemid 36618149)
20. S Soverini S Colarossi A Gnani 2006 GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia Clin Cancer Res 12 7374 7379 10.1158/1078-0432.CCR-06-1516 (Pubitemid 46095411)
21. S Branford Z Rudzki I Parkinson 2004 Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood 104 2926 2932 10.1182/blood-2004-03-1134 (Pubitemid 39434981)
22. N von Bubnoff PW Manley J Mestan 2006 Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) Blood 108 1328 1333 10.1182/blood-2005-12-010132 (Pubitemid 44232032)
23. HA Bradeen CA Eide T O'Hare KJ Johnson 2006 Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations Blood 108 2332 2338 10.1182/blood-2006-02-004580 (Pubitemid 44497517)